Baxter Bros Inc. Purchases 213 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Baxter Bros Inc. raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 17.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,441 shares of the pharmaceutical company’s stock after buying an additional 213 shares during the quarter. Baxter Bros Inc.’s holdings in Vertex Pharmaceuticals were worth $642,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Advisor OS LLC increased its position in Vertex Pharmaceuticals by 4.4% in the first quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company’s stock worth $263,000 after buying an additional 23 shares in the last quarter. Avidian Wealth Enterprises LLC increased its position in Vertex Pharmaceuticals by 2.1% in the first quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company’s stock worth $594,000 after buying an additional 25 shares in the last quarter. Strategic Blueprint LLC grew its position in shares of Vertex Pharmaceuticals by 1.7% during the first quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company’s stock worth $726,000 after purchasing an additional 25 shares in the last quarter. Newman Dignan & Sheerar Inc. grew its position in shares of Vertex Pharmaceuticals by 3.3% during the second quarter. Newman Dignan & Sheerar Inc. now owns 786 shares of the pharmaceutical company’s stock worth $350,000 after purchasing an additional 25 shares in the last quarter. Finally, Hager Investment Management Services LLC grew its position in shares of Vertex Pharmaceuticals by 0.5% during the first quarter. Hager Investment Management Services LLC now owns 5,411 shares of the pharmaceutical company’s stock worth $2,623,000 after purchasing an additional 27 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on VRTX. Wall Street Zen cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd. Wells Fargo & Company upgraded Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 target price for the company in a research report on Wednesday, August 6th. Scotiabank cut their target price on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a research report on Tuesday, August 5th. Leerink Partners upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and cut their target price for the stock from $458.00 to $456.00 in a research report on Thursday, September 25th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $494.43.

Insider Activity

In related news, Director Bruce I. Sachs acquired 5,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the purchase, the director directly owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Trading Up 2.6%

Shares of Vertex Pharmaceuticals stock opened at $421.15 on Thursday. The firm has a market cap of $107.98 billion, a PE ratio of 30.10 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.88. The stock has a 50 day moving average of $395.83 and a 200 day moving average of $440.97.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.28. The business had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same period last year, the company earned ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.